P. Sonawane

Multi-receptor targeting of glioblastoma

S. Tatter, Puja Sharma, W. Debinski, 2020 .

Metabolic characteristics of 13‐cis‐retinoic acid (isotretinoin) and anti‐tumour activity of the 13‐cis‐retinoic acid metabolite 4‐oxo‐13‐cis‐retinoic acid in neuroblastoma

C. Reynolds, Min H. Kang, A. Yu, 2014, British journal of pharmacology.

Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1)

David T. W. Jones, N. Jäger, S. Pfister, 2021, Acta Neuropathologica.

Multireceptor targeting of glioblastoma

S. Tatter, R. D'Agostino, Puja Sharma, 2020, Neuro-oncology advances.

Novel molecular multilevel targeted antitumor agents

W. Debinski, W. Priebe, I. Fokt, 2017, Cancer translational medicine.

315 Characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508

R. Swaby, M. Klichinsky, T. Condamine, 2022, Regular and Young Investigator Award Abstracts.

Abstract LB-049: Low plasma levels of 13-cis-retinoic acid (isotretinoin) and its active metabolite 4-oxo-13-cis-retinoic acid are associated with lower overall survival of high-risk neuroblastoma patients

A. Naranjo, Shengping Yang, J. Villablanca, 2017 .